Glycoengineered erythrocytes for better influenza vaccines
The objective of this ERC PoC project is to establish technical and commercial feasibility of our recently developed glycan-engineered red blood cells (RBCs) for antigenic characterization of circulating influenza A/H3N2 viruses....
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
BIO2015-72401-EXP
DISEÑO DE UNA TECNICA DE INHIBICION DE AGLUTINACION MEDIANTE...
67K€
Cerrado
SAMUFLU
Self amplifying RNA technology applied to the development of...
187K€
Cerrado
UNIFLUVAC
A novel universal influenza vaccine targeting epitopes of li...
149K€
Cerrado
ENDFLU
Evaluation of ratioNally Designed Influenza vaccines
14M€
Cerrado
GLYCOFLUP
Probing Molecular Recognition of the Avian and Human Influen...
169K€
Cerrado
Información proyecto Sugar-enabledVAC
Duración del proyecto: 20 meses
Fecha Inicio: 2022-06-28
Fecha Fin: 2024-02-29
Líder del proyecto
UNIVERSITEIT UTRECHT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The objective of this ERC PoC project is to establish technical and commercial feasibility of our recently developed glycan-engineered red blood cells (RBCs) for antigenic characterization of circulating influenza A/H3N2 viruses. Due to the rapid evolution of influenza A/H3N2 viruses, antigenic characterization by the widely used hemagglutination inhibition (HI) assay is not possible anymore. Continuous antigenic characterization of influenza A viruses is, however, essential for the development of protective seasonal vaccines. The ERC program sugar-enable has developed glycoengineered RBCs that make it possible again to antigenically characterize circulating A/H3N2 viruses by the standard HI assay, and it is expected that the cells will find application in hundreds of laboratories worldwide.